Zhou Zhengjun, Tian Junjie, Zhang Wenyan, Xiang Wei, Ming Yang, Chen Ligang, Zhou Jie
Department of Neurosurgery, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, P.R. China.
Sichuan Clinical Research Center for Neurosurgery, Luzhou, Sichuan 646000, P.R. China.
Oncol Lett. 2021 Jul;22(1):510. doi: 10.3892/ol.2021.12771. Epub 2021 May 3.
Oncolytic viruses have attracted widespread attention as biological anticancer agents that can selectively kill tumor cells without affecting normal cells. Although progress has been made in therapeutic strategies, the prognosis of patients with glioblastoma (GBM) remains poor and no ideal treatment approach has been developed. Recently, oncolytic herpes simplex virus (oHSV) has been considered a promising novel treatment approach for GBM. However, the therapeutic efficacy of oHSV in GBM, with its intricate pathophysiology, remains unsatisfactory due to several obstacles, such as limited replication and attenuated potency of oHSV owing to deletions or mutations in virulence genes, and ineffective delivery of the therapeutic virus. Multiple strategies have attempted to identify the optimal strategy for the successful clinical application of oHSV. Several preclinical trials have demonstrated that engineering novel oHSVs, developing combination therapies and improving methods for delivering oHSV to tumor cells seem to hold promise for improving the efficacy of this virotherapy.
溶瘤病毒作为一种能够选择性杀死肿瘤细胞而不影响正常细胞的生物抗癌剂，已引起广泛关注。尽管在治疗策略方面取得了进展，但胶质母细胞瘤（GBM）患者的预后仍然很差，尚未开发出理想的治疗方法。最近，溶瘤单纯疱疹病毒（oHSV）被认为是一种有前途的GBM新型治疗方法。然而，由于其复杂的病理生理学，oHSV在GBM中的治疗效果仍然不尽人意，这是由于几个障碍所致，例如由于毒力基因的缺失或突变导致oHSV的复制受限和效力减弱，以及治疗性病毒的递送无效。多种策略试图确定oHSV成功临床应用的最佳策略。几项临床前试验表明，改造新型oHSV、开发联合疗法以及改进将oHSV递送至肿瘤细胞的方法似乎有望提高这种病毒疗法的疗效。
